Metabolic Diseases Clinical Trial
Official title:
An Open-label Multi-cohort Dose-escalation Study to Evaluate the Tolerance, Safety, and Pharmacokinetics of GNR-055 (GENERIUM JSC, Russia) in Healthy Volunteers With a Single Intravenous Administration
Verified date | August 2020 |
Source | AO GENERIUM |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers
Status | Completed |
Enrollment | 20 |
Est. completion date | September 8, 2020 |
Est. primary completion date | September 8, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Men aged 18 to 50 years (inclusive) at the time of signing the Informed Consent Form; - Body mass index (BMI) 18.5 to 30 kg/m2, body weight of 50 to 90 kg; - A verified diagnosis as "healthy" (the diagnosis "healthy" is established on the basis of a detailed medical history, in the absence of deviations from normal values during a clinical examination, including measurement of blood pressure, respiratory rate, heart rate, body temperature, laboratory and instrumental (ECG) examination data); - A written informed consent to participate in the study in accordance with applicable laws in place and compliance with all the procedures and requirements/restrictions provided for by the study protocol; - Consent to use adequate methods of contraception (double barrier method-male or female (for partners of male research volunteers), condom with spermicide, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, cervical cap with spermicide). Exclusion Criteria: - Known hypersensitivity to idursulfase and/or to the medicinal product excipients; - Burdened allergy history; - Drug intolerance; - History of seizures; - Deposit injections or implants use of any other medicinal product three months before the Screening Visit; - An unusual way of living (night working, extreme physical activity); - Diarrhea dehydration, vomiting, or other causes within 24 hours before the Screening Visit; - Deviations from the normal values of the clinical, laboratory, and ECG examinations; - If there are acute or chronic diseases of the cardiovascular, bronchopulmonary, nervous, immune, and endocrine systems, diseases of the gastrointestinal tract, liver and biliary tract, kidney and urinary tract, blood and lymphatic system, a history of mental illness; - Positive results for hepatitis B or C markers, human immunodeficiency virus (HIV), and syphilis; - Acute infectious diseases less than four weeks before the Screening Visit; - Regular administration of medicinal products less than two weeks before the Screening Visit; - Systolic blood pressure (SBP) below 100 mm Hg or above 140 mm Hg; diastolic blood pressure (DBP) below 70 mm Hg or above 90 mm Hg; HR below 60 bpm or above 80 bpm; - Blood donation (450 mL or more of blood or plasma) less than three months before the Screening Visit; - Participation in human clinical studies of medicinal products less than three months before the Screening Visit; - Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 0.5 L of beer, 200 mL of dry wine, or 50 mL of strong spirits) OR history of alcoholism; - Alcohol exhale positive test; - Drug addiction, toxic substance abuse, a positive urine analysis for potent and narcotic substances, including cocaine, cannabis, amphetamine, barbiturates, benzodiazepines, and opioids; - Smoking more than 10 cigarettes per day; - Other reasons that, in the opinion of the investigator, prevent a volunteer from participating in the study or cause an unreasonable risk. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | FSAEI HE "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of Russian Federation | Moscow |
Lead Sponsor | Collaborator |
---|---|
AO GENERIUM |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with Adverse Events | Adverse events, Laboratory tests, Vital signs, Physical examination, 12-lead electrocardiogram, Allergic associated reaction, Infusion associated reaction, Antidrug antibody. | Day 7 ± 1 | |
Secondary | Serum pharmacokinetic parameters of GNR-055 | Serum concentration GNR-055, Pharmacokinetic parameters | Day 2 | |
Secondary | Cmax - Maximum Serum Concentration | Pharmacokinetic parameters | Day 2 | |
Secondary | AUC - Area Under the Curve | Pharmacokinetic parameters | Day 2 | |
Secondary | ?1/2 - Half-life | Pharmacokinetic parameters | Day 2 | |
Secondary | Kel - Elimination rate constant | Pharmacokinetic parameters | Day 2 | |
Secondary | MRT - Mean residence time | Pharmacokinetic parameters | Day 2 | |
Secondary | Cl - Clearance | Pharmacokinetic parameters | Day 2 | |
Secondary | Vz - volume of distribution | Pharmacokinetic parameters | Day 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02402985 -
Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics
|
N/A | |
Completed |
NCT02380846 -
The Metabolic Effects of Consuming Carbohydrate With Different Protein Types
|
N/A | |
Not yet recruiting |
NCT01916603 -
Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development
|
N/A | |
Completed |
NCT01616082 -
Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)
|
N/A | |
Completed |
NCT01737164 -
Effect of Age on Glucose and Lipid Metabolism
|
N/A | |
Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
Enrolling by invitation |
NCT00628199 -
Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability
|
||
Recruiting |
NCT04958109 -
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
|
Phase 1 | |
Completed |
NCT02275429 -
Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal
|
N/A | |
Completed |
NCT01968720 -
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT01719913 -
The Effect of Gluten on Gut Microbiome and Metabolic Health.
|
N/A | |
Completed |
NCT01705782 -
The Effects of Amino Acid Supplement During Acute Inflammation.
|
N/A | |
Completed |
NCT01708681 -
Lean Seafood Intake and Postprandial Metabolism
|
N/A | |
Completed |
NCT01435382 -
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
|
Phase 1 | |
Recruiting |
NCT02629926 -
Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors
|
Phase 4 | |
Completed |
NCT00707746 -
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
|
Phase 2 | |
Completed |
NCT00550706 -
Drug Utilization Prevalence in a Pediatric Care Medical Center
|
N/A | |
Completed |
NCT03941392 -
Nutritional Study in Spanish Pediatric Population
|
||
Terminated |
NCT02440945 -
Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People
|
N/A | |
Not yet recruiting |
NCT06000605 -
Brain Substrate Switch to Ketones and Lactate
|
N/A |